OH2 Injection in Combination With HX008 for Melanoma.
A phase 1/2 trial of Pucotenlimab in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
Overview
OH2 Injection in Combination With HX008 for Melanoma. is a phase 1/2 interventional study registered as NCT04616443 by Binhui Biopharmaceutical Co., Ltd., with 60 participants planned, started 2020-12-01 and due to reach its primary completion in 2025-11-30. Interventions recorded: OH2 injection, HX008 injection. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Setting
Phase Ib Study of the Combination Use of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) and HX008 Injection in the Treatment of Melanoma
Phase
Phase 1/2
Sponsor
Binhui Biopharmaceutical Co., Ltd.
Registry
Enrolled
60